Transaction will never close. No way is Obi valued at $150M. If it does, poor saps who buy. My money is betting against. The cash still is chup change given the current systemic problems with FIDO and OPTR, buyer beware!
Optimer Biotechnology is a privately-held Taiwanese biopharma company with rights to fidoxamicin there and their own pipeline. Hank McKinnell is chairman of the BOD there as well. This is a done deal for all intents and kudos to OPTR for extracting another $60M cash for their stake which will be worth another $1.26/share to OPTR